Opportunity Information: Apply for RFA DA 23 028
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is soliciting applications for a grant opportunity titled "NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)" under Funding Opportunity Number RFA-DA-23-028 (CFDA 93.279). The central purpose of this opportunity is to fund exploratory, basic research that helps explain how structural racism and interpersonal racism shape neurocognitive processes in ways that may influence a persons path toward or away from substance use and substance use disorder. A key emphasis is on generating knowledge that can directly inform prevention efforts, meaning the work is intended to clarify mechanisms that prevention programs could realistically target, rather than only documenting disparities.
This opportunity is linked to NEPS Concept #1862 and focuses on unpacking structural racism into meaningful sub-components and testing how those components affect neurocognition. In practical terms, the announcement is encouraging researchers to move beyond broad, single measures of racism and instead break structural racism down into specific, measurable features and exposures (for example, policy-driven resource deprivation, neighborhood disinvestment, educational and employment inequities, criminal legal system inequities, housing segregation, or unequal access to healthcare), then study how those exposures translate into changes in cognitive and brain-related processes. The neurocognitive angle is central: applicants are expected to investigate mechanisms such as learning, reward processing, stress responsivity, executive function, attention, memory, emotion regulation, decision-making, inhibitory control, and related brain-behavior pathways that could plausibly connect racist structures and experiences to substance use risk, escalation, or persistence across time.
The grant uses the NIH R61/R33 phased innovation mechanism. This structure is designed to support a two-stage project where the early phase (R61) is typically used to establish feasibility, refine measures, validate approaches, or produce early mechanistic evidence, and the second phase (R33) supports a more expanded set of studies once pre-specified milestones are met. In other words, the mechanism is intended for projects that need an initial, milestone-driven developmental period before scaling into a larger, more definitive investigation. The "Clinical Trial Optional" designation indicates that applicants may propose studies that meet the NIH definition of a clinical trial, but they are not required to do so; both clinical trial and non-clinical trial research designs can fit, depending on the questions being asked and the methods used.
The scientific scope highlights two intertwined priorities. First, it invites research on interpersonal racism, which may include direct experiences of discrimination, bias, and racist treatment and the ways these experiences alter cognition and stress-related neurobiology. Second, it prioritizes parsing structural racism into component exposures, then linking those exposures to neurocognitive outcomes relevant to substance use trajectories. The prevention emphasis means that projects should ideally point toward modifiable mechanisms or leverage points (for example, identifying which neurocognitive pathways are most affected by particular structural conditions, when during development those effects are strongest, and which protective factors or contexts may buffer harm), thereby producing evidence that could guide preventive interventions, policies, or upstream strategies.
Eligibility is broad and includes many common U.S. applicant types: state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The announcement explicitly calls out additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions, as well as Indian/Native American Tribal Governments other than federally recognized ones.
Foreign involvement is restricted in a specific way. Non-domestic (non-U.S.) entities and non-domestic (non-U.S.) components of U.S. organizations are not eligible to apply as the applicant organization. However, foreign components, as defined in the NIH Grants Policy Statement, are allowed. That generally means a U.S.-based applicant can include certain foreign components or collaborations when they are scientifically justified and consistent with NIH policy, even though a foreign institution cannot be the primary applicant.
From the administrative details provided, this is a discretionary grant opportunity in the Education and Health activity category. The original closing date listed is 2024-11-14. An award ceiling of $500,000 is provided in the listing, which signals an upper bound associated with the opportunity as summarized here. The posting traces back to a creation date of 2022-08-09.
Overall, the opportunity is aimed at researchers who can connect structural and interpersonal racism to measurable neurocognitive mechanisms that influence substance use trajectories, with a strong preference for work that can clarify actionable targets for prevention. Competitive projects will typically be those that are conceptually precise about what aspect of structural racism is being measured, methodologically strong in linking those exposures to neurocognitive outcomes, and clear about how the resulting mechanistic insights could translate into real-world prevention approaches rather than remaining purely descriptive.Apply for RFA DA 23 028
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2022-08-09.
- Applicants must submit their applications by 2024-11-14. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Education, Health
Next opportunity: Physiomimetics and Organoids for Reproductive Health (R01 Clinical Trial Not Allowed)
Previous opportunity: The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 23 028
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 23 028) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional) Apply for RFA DA 23 026 Funding Number: RFA DA 23 026 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) Apply for RFA DA 23 029 Funding Number: RFA DA 23 029 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional) Apply for RFA DA 23 023 Funding Number: RFA DA 23 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed) Apply for RFA DA 23 025 Funding Number: RFA DA 23 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional) Apply for RFA DA 23 024 Funding Number: RFA DA 23 024 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional) Apply for RFA DA 23 031 Funding Number: RFA DA 23 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Clinical Trial Not Allowed) Apply for RFA DA 23 050 Funding Number: RFA DA 23 050 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Basic Experimental Studies with Humans Required) Apply for RFA DA 23 055 Funding Number: RFA DA 23 055 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional) Apply for RFA CA 22 054 Funding Number: RFA CA 22 054 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) Apply for RFA CA 22 041 Funding Number: RFA CA 22 041 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) Apply for RFA DA 23 056 Funding Number: RFA DA 23 056 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA CA 22 030 Funding Number: RFA CA 22 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) Apply for RFA CA 22 029 Funding Number: RFA CA 22 029 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required) Apply for RFA CA 22 028 Funding Number: RFA CA 22 028 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) Apply for PAR 22 234 Funding Number: PAR 22 234 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) Apply for PAR 22 200 Funding Number: PAR 22 200 Agency: National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional) Apply for RFA CA 22 050 Funding Number: RFA CA 22 050 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) Apply for PAR 22 202 Funding Number: PAR 22 202 Agency: National Institutes of Health Category: Education, Health Funding Amount: $5,000,000 |
| Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) Apply for PAR 22 243 Funding Number: PAR 22 243 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed) Apply for PAR 22 242 Funding Number: PAR 22 242 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 23 028", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
